The use of clozapine and other antipsychotics for treatment-resistant schizophrenia at the brazilian psychosocial care centers in Joao Pessoa, PB, Brazil
DOI:
https://doi.org/10.25118/2763-9037.2023.v13.511Keywords:
resistant schizophrenia, clozapine, antipsychoticsAbstract
Introduction: Although Clozapine is the drug recommended for treatment-resistant schizophrenia (TRS), it is underprescribed. Objectives: To analyze the pattern of clozapine prescription and use of other antipsychotics for patients with treatment-resistant schizophrenia in community mental health centers in Joao Pessoa. Methods: Antipsychotic prescriptions and medical records of patients with schizophrenia were reviewed. The psychiatrists of the services completed a survey on the difficulties associated with prescribing clozapine. Results: Among 381 patients with schizophrenia, 102 (26.8%) met the TRS criteria. Forty of the TRS patients (39.2%) were in polypharmacy; 25 in atypical antipsychotic monotherapy (24.6%), 3 with typical antipsychotic monotherapy (3%), and only 34 were using clozapine (33.3%). An important obstacle is the logistics required for blood counts routine. Conclusion: The most TRS patients (66.7%) was prescribed non-clozapine treatment, mostly polypharmacy, at the Brazilian Psychosocial Care Centers in Joao Pessoa.
Downloads
Metrics
References
Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull. 1995;21:567. https://doi.org/10.1093/schbul/21.4.567 - PMid:8749885 DOI: https://doi.org/10.1093/schbul/21.4.567
Kane J, Hognifeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-96. https://doi.org/10.1001/archpsyc.1988.01800330013001 - PMid:3046553 DOI: https://doi.org/10.1001/archpsyc.1988.01800330013001
Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q. 2000;71(4):373-84. https://doi.org/10.1023/A:1004640408501 - PMid:11025914 DOI: https://doi.org/10.1023/A:1004640408501
Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2007;30:511-33. https://doi.org/10.1016/j.psc.2007.04.001 - PMid:17720034 DOI: https://doi.org/10.1016/j.psc.2007.04.001
Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Especializada e Temática. Centros de Atenção Psicossocial e Unidades de Acolhimento como lugares da atenção psicossocial nos territórios: orientações para elaboração de projetos de construção, reforma e ampliação de CAPS e de UA. Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Especializada e Temática. Brasília: Ministério da Saúde, 2015. 44 p. https://bvsms.saude.gov.br/bvs/publicacoes/centros_atencao_psicossocial_unidades_acolhimento.pdf
Brasil. Ministério da Saúde. Portaria n. 336, de 19 de fevereiro de 2002. Estabelece que os Centros de Atenção Psicossocial poderão constituir-se nas seguintes modalidades de serviços: CAPS I, CAPS II e CAPS III, definidos por ordem crescente de porte/complexidade e abrangência populacional. https://www.gov.br/saude/pt-br/acesso-a-informacao/acoes-e-programas/caps
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. https://doi.org/10.1016/s0140-6736(13)60733-3 - PMid:23810019 DOI: https://doi.org/10.1016/S0140-6736(13)60733-3
Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka PJ. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627. https://doi.org/10.1016/S0140-6736(09)60742-X PMid:19595447 DOI: https://doi.org/10.1016/S0140-6736(09)60742-X
Goren JL, Meterko M, Williams S, Young GJ, Baker E, Chou CH, Bauer MS. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv. 2013;64(6):527-533. https://doi.org/10.1176/appi.ps.002022012 - PMid:23450334 DOI: https://doi.org/10.1176/appi.ps.002022012
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36:94-103. https://doi.org/10.1093/schbul/sbp130 - PMid:19955388 - PMCid:PMC2800150 DOI: https://doi.org/10.1093/schbul/sbp130
Lee B, Walker V. Polypharmacy as the initial second-generation antipsychotic treatment. Psychiatr Serv. 2008;59:717. https://doi.org/10.1176/ps.2008.59.7.717 - PMid:18586985 DOI: https://doi.org/10.1176/ps.2008.59.7.717
Tsutsumi C, Uchida H, Suzuki T, Watanabe K, Takeuchi H, Nakajima S, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Kapur S. The evolution of antipsychotic switch and polypharmacy in natural practice: a longitudinal perspective. Schizophr Res. 2011;130:40-46. https://doi.org/10.1016/j.schres.2011.05.013 - PMid:21624824 DOI: https://doi.org/10.1016/j.schres.2011.05.013
Thien K, O'Donoghue B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: a literature review. Early Interv Psychiatry. 2019;13-18. https://doi.org/10.1111/eip.12683 - PMid:29984888 DOI: https://doi.org/10.1111/eip.12683
Patrick V, Levin E, Schleifer S. Antipsychotic polypharmacy: is there evidence for its use? J Psychiatr Pract. 2005;11(4):248-257. https://doi.org/10.1097/00131746-200507000-00005 PMid:16041235 DOI: https://doi.org/10.1097/00131746-200507000-00005
Janssen B, Weinmann S, Berger M, Gaebel W. Validation of polypharmacy process measures ininpatient schizophrenia care. Schizophr Bull. 2004;30(4):1023-33. https://doi.org/10.1093/oxfordjournals.schbul.a007117 - PMid:15954205 DOI: https://doi.org/10.1093/oxfordjournals.schbul.a007117
Sernyak MJ, Rosenheck RA. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatr Serv. 2008;59:567-569. https://doi.org/10.1176/ps.2008.59.5.567 - PMid:18451019 DOI: https://doi.org/10.1176/ps.2008.59.5.567
Tan CH, Shinfuku N, Sim K. Psychotropic prescription practices in east Asia: looking back and peering ahead. Curr. Opin. Psychiatry. 2008;21:645-650. https://doi.org/10.1097/YCO.0b013e32830e6dc4 - PMid:18852575 DOI: https://doi.org/10.1097/YCO.0b013e32830e6dc4
Silveira ASA, Rocha DMLV, Attux CRF, Daltio CS, Silva LA, Elkis H, Kane JM, Bressan RA. Patterns of clozapine and other antipsychotics prescriptions in patients with treatment-resistant schizophrenia in community mental health centers in São Paulo, Brazil. Arch Clin Psychiatry (São Paulo). 2015;42(6):165-170. https://doi.org/10.1590/0101-60830000000069 DOI: https://doi.org/10.1590/0101-60830000000069
Wheeler AJ. Treatment pathway and patterns of clozapine prescribing or schizophrenia in New Zealand. Ann Pharmacother. 2008;42(6):852-860. https://doi.org/10.1345/aph.1K662 PMid:18477732 DOI: https://doi.org/10.1345/aph.1K662
Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499-507. https://doi.org/10.1001/jamapsychiatry.2018.4320 - PMid:30785608 - PMCid:PMC6495354 DOI: https://doi.org/10.1001/jamapsychiatry.2018.4320
Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24(7):965-971. https://doi.org/10.1177/0269881108100320 - PMid:19164499 DOI: https://doi.org/10.1177/0269881108100320
Howes OD, McCutcheon R, Agid O, Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MAP, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JEC, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller H-J, Nakajima S, Pantelis C, Marques TR, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JTR, Kane J, Correll CU. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216-229. https://doi.org/10.1176/appi.ajp.2016.16050503 - PMid:27919182 - PMCid:PMC6231547 DOI: https://doi.org/10.1176/appi.ajp.2016.16050503
Guyatt G. Evidence-based medicine. JAMA. 1992;268(17):2420. https://doi.org/10.1001/jama.1992.03490170092032 - PMid:1404801 DOI: https://doi.org/10.1001/jama.1992.03490170092032
Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. The Lancet. 2017;390(10092):415-423. https://doi.org/10.1016/S0140-6736(16)31592-6 PMid:28215660 DOI: https://doi.org/10.1016/S0140-6736(16)31592-6
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
License
Copyright (c) 2023 Gabriela Jorge do Nascimento, Heydrich Lopes Virgulino de Medeiros
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
